OTC drug review
Executive SummaryFDA announced in the April 29 Federal Register that three final monographs were projected for publication in April 1985: alertness aid, anthelmintic and otic drug products. Eight tentative final monographs were also projected for publication during the month (anorectal, fever blister, topical hormone, internal analgesic, internal deodorant, male genital desensitizer, smoking deterrent, and weight control products). However, the agency had previously projected October 1984 publication dates for five of these monographs (alertness aid, anorectal, anthelmintic, topical hormone, and internal analgesic drug products).
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.